Open-Label, Parallel-Group Phase 1 Study to Investigate the Effect of Various Degrees of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of the c-Met Kinase Inhibitor Tepotinib
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2018
At a glance
- Drugs Tepotinib (Primary)
- Indications Adenocarcinoma; Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors EMD Serono Research & Development Institute
- 23 Aug 2018 Planned End Date changed from 27 Aug 2018 to 21 Sep 2018.
- 23 Aug 2018 Planned primary completion date changed from 27 Aug 2018 to 21 Sep 2018.
- 29 Jun 2018 Planned number of patients changed from 18 to 24.